Hypothesis: Parkinson's disease, reward deficiency syndrome and addictive effects of levodopa;Hipótesis: Enfermedad de Parkinson, síndrome de deficiencia de recompensa y efectos adictivos de la levodopa

Neurologia

Volumn 19, Issue 3, 2004, Pages 117-127

  Linazasoro, G ^a   Van Blercom, N ^a   Lasa, A ^a  

^a HOSPITAL QUIRÓN   (Spain)

Author keywords

Addiction; Dopamine; Dyskinesias; Parkinson's disease; Reward deficiency syndrome

Indexed keywords

ANTIPARKINSON AGENT; DOPAMINE; LEVODOPA;

ADDICTION; ADULT; CASE REPORT; DRUG ACTIVITY; DRUG EFFECT; DYSKINESIA; HUMAN; LIMBIC CORTEX; PARKINSON DISEASE; PATHOPHYSIOLOGY; PULSATILE DRUG RELEASE; REVIEW; REWARD; REWARD DEFICIENCY SYNDROME; SYNDROME;

ADULT; ANTIPARKINSON AGENTS; BEHAVIOR, ADDICTIVE; DOPAMINE; DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; HUMANS; LEVODOPA; MIDDLE AGED; NEURONAL PLASTICITY; PARKINSON DISEASE; REWARD; VISUAL CORTEX;

EID: 1942455231     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Hyman SE, Malenka RC. Addiction and the brain: the neurobiology of compulsion and its persistence. Nat Rev Neurosci 2001;2:695-703.
2. Everitt BJ, Wolf ME. Psychomotor stimulant addiction: a neural system perspective. J Neurosci 2002;22:3312-20.
3. Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM. It could be habit forming: drugs of abuse and striatal synaptic plasticity. Trends Neurosci 2003;26:184-92.
4. Schultz W. Multiple reward signals in the brain. Nature Rev Neurosci 2000;1:199-207.
5. Nestler EJ. Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2001;2:119-28.
6. Breiter HC, Gollub RL, Weisskoff RM, Kennedy DN, Makris N, Berke JD, et al. Acute effects of cocaine on human brain activity and emotion. Neuron 1997;19:591-611.
7. Blum K, Braverman ER, Holder JM, Lubar JF, Monastra VJ, Miller D, et al. Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviours. J Psychoactive Drugs 2000;32:S1-S112.
8. Comings DE, Blum K. Reward deficiency syndrome: genetic aspects of behavioural disorders. Prog Brain Res 2000;126:325-41.
9. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Cull JG, et al. The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 1996;89:396-400.
10. a ed. Nueva York: Lippincott Williams and Wilkins, 2002; p. 256-70.
11. Kish SH, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988;318:876-80.
12. Poewe W, Luginger E. Depression in Parkinson's disease. Neurology 1999;49(Suppl 3):2-6.
13. Seedat S, Kesler S, Niehaus DJH, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depression and Anxiety 2000;11:185-6.
14. Geschwandtner U, Aston J, Renaud S, Fuhr P. Pathologic gambling in patients with Parkinson's disease. Clin Neuropharmacol 2001;24:170-2.
15. Molina JA, Sainz-Artiga MJ, Fraile A, Jiménez-Jiménez FJ, Villanueva C, Orti-Pareja M, et al. Pathologic gambling in Parkinson's disease: a behavioral manifestation of pharmacologic treatment? Mov Disord 2000;15:869-72.
16. Berke JD, Hyman SE. Addiction, dopamine, and the molecular mechanisms of memory. Neuron 2000;25:515-32.
17. Nausieda PA. Sinemet abusers. Clin Neuropharmacol 1985;8:318-27.
18. Tack E, De Cuypere G, Jannes C, Remouchamps A. Levodopa addiction. A case study. Acta Psychiatr Scand 1988;78:356-60.
19. Priebe S. Levodopa dependence. A case report. Pharmacopsychiat 1984;17:109-10.
20. Spigset O, von Scheele C. Levodopa dependence and abuse in Parkinson's disease. Pharmacotherapy 1997;17:1027-30.
21. Merims D, Galili-Mosberg R, Melamed E. Is there addiction to levodopa in patients with Parkinson's disease? Mov Disord 2000;15:1014-6.
22. Sánchez Ramos J. The straight dope on addiction to dopamimetic drugs. Mov Disord 2001;17:223-5.
23. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJ. Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000;68:423-8.
24. Koob GF, LeMoal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278:52-8.
25. De la Fuente R, Schulzer M, Stoessl AJ. The placebo effect in neurological disorders. Lancet Neurology 2002;1:85-91.
26. De la Fuente R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-6.
27. Goetz CG, Leurgans S, Raman R, Stebbins GT. Objective changes in motor functioin during placebo treatment in Parkinson's disease. Neurology 2000;54:710-714.
28. Howell LL, Wilcocx KM. Functional imaging and neurochemical correlates of stimulant self-administration in primates. Psychopharmacology 2002;163:352-61.
29. Spinella M. Relationship between drug use and prefrontal-associated traits. Addict Biol 2003;8:67-74.
30. Graybiel AM, Canales JJ, Capper-Loup C. Levodopa-induced dyskinesias and dopamine-dependent stereotypies: a new hypothesis. Trends Neurosci 2000;23:S71-7.
31. Moratalla R. Receptores dopaminérgicos implicados en la plasticidad sináptica del estriado. Neurologia 2002;17(Suppl 1):37-45.
32. Gerfen CR. Molecular effects of dopamine on striatal projection pathways. Trends Neurosci 2000;23:S64-S70.
33. Calon F, Tahar AH, Blanchet PJ, Morisette M, Grondin R, Goulet M, et al. Dopamine receptor stimulation: behavioural and biochemical consequences. Trends Neurosci 2000;23:S92-S100.
34. Pepe A, Dambrosia JM, Chase TN. Risk factors for motor response complications in levodopa-treated parkinsonian patients. Adv Neurol 1993;60:698-702.
35. Blanchet PJ, Allard P, Gregoire L, Tardif F, Bédard PJ. Risk factors for peak dose dyskinesia in 100 L-dopa treated parkinsonian patients. Can J Neurol Sci 1992;23:189-93.
36. Boyce S, Rupniak NMJ, Steventon MJ, Iversen SD. Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. Clin Neuropharmacol 1990;13:448-458.
37. Di Monte DA, McCormack A, Petzinger G, Janson AM, Quik M, Langston WJ. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000;15:459-66.
38. Oliveri RL, Annesi G, Zappia M, Civitelli B, Montesanti R, Branca D, et al. Dopamine D2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD. Neurology 1999;53:1425-30.
39. Ishikawa A, Tsuji S. Clinical analysis of 17 patients in 12 japanese families with autosomal-recessive type juvenile parkinsonism. Neurology 1996;47:160-6.
40. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 1996;19:19-24.
41. Markou A, Koob GF. Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 1991;4:17-26.
42. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002;51:686-93.
43. Blanchet PJ, Gȯmez-Mancilla Bėdard PJ. Dopa-induced peak-dose dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys. J Neural Transm 1995;45(Suppl):103-12.
44. Olds J, Milner P. Positive reinforcement produced by electrical stimulation of septal and other regions of rat brain. J Comp Physiol Psych 1954;47:419-27.
45. Reynolds JNJ, Wickens JR. Self-stimulation and synaptic plasticity. Adv Behav Biology (The basal ganglia VII) 2002;52:299-312.
46. Ingram SL. Dopamine transporter-mediated conductances increase excitability of midbrain dopamine neurons. Nature Neurosci 2002;5:971-8.
47. Little KY, Krolewski DM, Zhang L, Cassin BJ. Loss of striatal vesicular monoamine transporter protein (VMAT2) in human cocaine users. Am J Psychiatry 2003;160:47-55.
48. Carlezon WA, Nestler EJ. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse. Trends Neurosci 2002;25:610-5.
49. Stephens DN, Mead AN. What role do GluR1 subunits play in drug abuse? Trends Neurosci 2003;26:181-3.
50. Schoffelmeer ANM, De Vries TJ, Binnekade R. Stimulant-induced behavioural sensitization depends on nicotinic receptor activation. J Neurosci 2002;22:3269-76.
51. Linazasoro G. Anticholinergics and dyskinesias. Mov Disord 1994;9:689.
52. Lasa A, Van Blercom N, Linazasoro G. Donepezil in the treatment of dysexecutive syndrome in Parkinson's disease: a pilot study. J Neurol (en prensa).
53. Brotchie JM. Advances in understanding the neural mechanisms underlying L-DOPA-induced dyskinesias. Adv Neurol 1999;80:71-85.
54. Laviolette SR, Alexon TO, van der Kooy D. Lesions of the tegmental pedunculopontine nucleus block the rewarding effects and reveal the aversive effects of nicotine in the ventral tegmental area. J Neurosci 2002;22:8653-60.
55. Picconi B, Centonze D, Hakansson K, Bernardi G, Greengard P, Fisone G, et al. Loss of bidirectional striatal synaptic plasticity in L-Dopa-induced dyskinesia. Nat Neurosci 2003;6:501-5.
56. Dunnet S. L-Dopa, dyskinesia and striatal plasticity. Nature Neurosci 2003;6:437-8.
57. Kuhar MJ, Joyce A, Dominguez G. Genes in drug abuse. Drug Alcohol Depend 2001;62:157-62.
58. Bibb JA, Chen J, Taylor JR, Svenningson P, Nishi A, Snyder GL. Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature 2001;410:376-380.
59. Andersson M, Westin JE, Cenci MA. Time course of striatal DeltaFosB-like immunoreactivity and prodynorphin mRNA levels after discontinuation of chronic dopaminomimetic treatment. Eur J Neurosci 2003;17:661-6.
60. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 2000;47(Suppl 1):90-104.
61. Wang JQ, Mao L, Parelkar NK, Tang Q, Liu Z, Sarwar S, et al. Glutamate-regulated behaviour, transmitter release, gene expression and addictive plasticity in the striatum: roles of metabotropic glutamate receptors. Curr Pharmacol 2003;1:1-20.
62. Nicholetti F, Bruno V, Copani A, Casabona G, Knopfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 1996;19:267-71.
63. Nygaard TJ, Wooten GF. Dopa-responsive dystonia. Neurology 1998;50:853-5.
64. Rajput AH, Fenton M, Birdi S, Macaulay R. Is levodopa toxic to the human substantia nigra? Mov Disord 1997;12:634-8.
65. Muriel MP, Orieux G, Hirsch E. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats. Mov Disord 2002;17:1174-9.
66. Gerfen CR. Dopamine receptor function in the basal ganglia. Clin Neuropharmacol 1995;18:S162-S77.